Medibact GuidesShop at Medibact

Stacking Module

Melanotan II Stacking Module

Melanotan II has the widest gap in this catalog between how casually it is discussed and how substantial its documented safety concerns are. Its stacking picture is dominated by one fact: it is a non-selective melanocortin agonist, so it collides with PT-141 and produces effects across several systems at once.

Melanotan II Guide at MedibactMelanotan II calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking Melanotan II

  • Melanotan II is a non-selective melanocortin-receptor agonist. It is not FDA-approved, and regulatory bodies in several countries have issued warnings about it.
  • Non-selectivity means its effects are not confined to pigmentation — sexual-function effects, nausea and flushing are commonly reported, which is why it collides with PT-141 rather than complementing it.
  • Reported concerns include new or changing moles and the need for dermatological surveillance, which is a specific and serious consideration no other compound here carries.
  • No controlled trial has studied it combined with anything.

Combinations in detail

Melanotan II + PT-141

Non-selective melanocortin agonist + selective melanocortin agonist
Why it is proposed
Presented as separating pigmentation from sexual function, but Melanotan II already produces both.
What is reported in practice
Reported as separate subcutaneous compounds.
Cautions specific to this combination
A class collision with overlapping side effects. PT-141's documented blood-pressure effects plus Melanotan II's cardiovascular and nausea profile is the least advisable pairing in this catalog.

Melanotan II + GHK-Cu

Melanocortin agonist + copper peptide
Why it is proposed
Reported together in skin and aesthetic discussion through unrelated mechanisms — pigmentation versus matrix remodeling.
What is reported in practice
Separate compounds; GHK-Cu's own strongest evidence is topical.
Cautions specific to this combination
Neither addresses the mole-surveillance concern that accompanies Melanotan II. Copper accumulation is GHK-Cu's separate constraint.

Melanotan II + BPC-157

Melanocortin agonist + repair peptide
Why it is proposed
Community-reported general recovery support alongside pigmentation use; unrelated mechanisms.
What is reported in practice
Separate vials and schedules.
Cautions specific to this combination
No combination data; does not mitigate Melanotan II's own concerns.

What to avoid, and why

  • Combining Melanotan II with PT-141 or Melanotan I — all melanocortin agonists, with compounding side effects.
  • Treating pigmentation as its only effect; non-selectivity means several systems are affected at once.
  • Proceeding without dermatological surveillance given reported changes to moles — this is the one safety consideration here that is specific, serious and actionable.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.